SEC Form 4 · accession 0000899243-19-000776
Urovant Sciences Ltd. · UROV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christine Ocampo
Officer — PFAO;CAO/Urovant Sciences, Inc
Period of report
Jan 6, 2019
Accepted (ET)
Jan 8, 2019 · 5:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001740547
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.88 | Jan 6, 2019 | A | 70,000 | A | — | Jan 6, 2029 | Common Shares | 70,000 | 70,000 | D |
Explanation of responses
- F125% of the total shares underlying the option shall vest and become exercisable on January 2, 2020; the remaining shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date.
Remarks
Exhibit List - Exhibit 24.1 - Power of Attorney